BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialRedline//FDA calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialRedline FDA calendar
X-WR-CALDESC:PDUFA dates and FDA decisions with an exact reported day. Date
 s reported only as a month\, quarter or year are listed at https://trialre
 dline.com/fda-calendar
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:regulatory-event-330@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251007
DTEND;VALUE=DATE:20251008
SUMMARY:JASCAYD: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA218764\nDetails: https://t
 rialredline.com/drugs/jascayd-9d9802d0
URL:https://trialredline.com/drugs/jascayd-9d9802d0
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-331@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251007
DTEND;VALUE=DATE:20251008
SUMMARY:LASIX ONYU: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA217294\nDetails: https://t
 rialredline.com/drugs/lasix-onyu-e8bfc2c4
URL:https://trialredline.com/drugs/lasix-onyu-e8bfc2c4
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-329@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251016
DTEND;VALUE=DATE:20251017
SUMMARY:FERABRIGHT: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219868\nDetails: https://t
 rialredline.com/drugs/ferabright-c9f3f00e
URL:https://trialredline.com/drugs/ferabright-c9f3f00e
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-328@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251017
DTEND;VALUE=DATE:20251018
SUMMARY:EPIOXA HD/EPIOXA KIT: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219910\nDetails: https://t
 rialredline.com/drugs/epioxa-hd-epioxa-kit-815b279f
URL:https://trialredline.com/drugs/epioxa-hd-epioxa-kit-815b279f
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-327@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251022
DTEND;VALUE=DATE:20251023
SUMMARY:CONTEPO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA212271\nDetails: https://t
 rialredline.com/drugs/contepo-79f136cc
URL:https://trialredline.com/drugs/contepo-79f136cc
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-325@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251023
DTEND;VALUE=DATE:20251024
SUMMARY:JAVADIN: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220256\nDetails: https://t
 rialredline.com/drugs/javadin-274271e9
URL:https://trialredline.com/drugs/javadin-274271e9
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-326@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251023
DTEND;VALUE=DATE:20251024
SUMMARY:BLENREP: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761440\nDetails: https://t
 rialredline.com/drugs/blenrep-a5ae4aec
URL:https://trialredline.com/drugs/blenrep-a5ae4aec
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-324@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251024
DTEND;VALUE=DATE:20251025
SUMMARY:LYNKUET: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219469\nDetails: https://t
 rialredline.com/drugs/lynkuet-867b65c1
URL:https://trialredline.com/drugs/lynkuet-867b65c1
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-322@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251029
DTEND;VALUE=DATE:20251030
SUMMARY:OSVYRTI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761424\nDetails: https://t
 rialredline.com/drugs/osvyrti-4befbdb7
URL:https://trialredline.com/drugs/osvyrti-4befbdb7
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-323@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251029
DTEND;VALUE=DATE:20251030
SUMMARY:JUBEREQ: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761424\nDetails: https://t
 rialredline.com/drugs/jubereq-77cb0a57
URL:https://trialredline.com/drugs/jubereq-77cb0a57
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-321@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251103
DTEND;VALUE=DATE:20251104
SUMMARY:KYGEVVI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219792\nDetails: https://t
 rialredline.com/drugs/kygevvi-37de4ef3
URL:https://trialredline.com/drugs/kygevvi-37de4ef3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-153@trialredline.com
DTSTAMP:20261006T075145Z
DTSTART;VALUE=DATE:20251113
DTEND;VALUE=DATE:20251114
SUMMARY:Ziftomenib: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220305\nDetails: https://t
 rialredline.com/drugs/ziftomenib-9add7c60
URL:https://trialredline.com/drugs/ziftomenib-9add7c60
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-319@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251113
DTEND;VALUE=DATE:20251114
SUMMARY:KOMZIFTI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220305\nDetails: https://t
 rialredline.com/drugs/komzifti-28a7baf5
URL:https://trialredline.com/drugs/komzifti-28a7baf5
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-320@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251113
DTEND;VALUE=DATE:20251114
SUMMARY:POHERDY: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761450\nDetails: https://t
 rialredline.com/drugs/poherdy-908a70ab
URL:https://trialredline.com/drugs/poherdy-908a70ab
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-318@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251119
SUMMARY:REDEMPLO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219947\nDetails: https://t
 rialredline.com/drugs/redemplo-dfbc8c1c
URL:https://trialredline.com/drugs/redemplo-dfbc8c1c
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-317@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251119
DTEND;VALUE=DATE:20251120
SUMMARY:HYRNUO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219972\nDetails: https://t
 rialredline.com/drugs/hyrnuo-b52005a0
URL:https://trialredline.com/drugs/hyrnuo-b52005a0
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-316@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251125
DTEND;VALUE=DATE:20251126
SUMMARY:VOYXACT: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761434\nDetails: https://t
 rialredline.com/drugs/voyxact-c5b4bb0e
URL:https://trialredline.com/drugs/voyxact-c5b4bb0e
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-315@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251128
DTEND;VALUE=DATE:20251129
SUMMARY:ARMLUPEG: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761212\nDetails: https://t
 rialredline.com/drugs/armlupeg-6d6e5f36
URL:https://trialredline.com/drugs/armlupeg-6d6e5f36
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-314@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251211
DTEND;VALUE=DATE:20251212
SUMMARY:DAYBUE STIX: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219884\nDetails: https://t
 rialredline.com/drugs/daybue-stix-28326715
URL:https://trialredline.com/drugs/daybue-stix-28326715
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-311@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251212
DTEND;VALUE=DATE:20251213
SUMMARY:NUZOLVENCE: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219491\nDetails: https://t
 rialredline.com/drugs/nuzolvence-a2db0b40
URL:https://trialredline.com/drugs/nuzolvence-a2db0b40
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-312@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251212
DTEND;VALUE=DATE:20251213
SUMMARY:CARDAMYST: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA218571\nDetails: https://t
 rialredline.com/drugs/cardamyst-13b152d4
URL:https://trialredline.com/drugs/cardamyst-13b152d4
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-313@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251212
DTEND;VALUE=DATE:20251213
SUMMARY:LEROCHOL: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761427\nDetails: https://t
 rialredline.com/drugs/lerochol-743d3058
URL:https://trialredline.com/drugs/lerochol-743d3058
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-309@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251216
DTEND;VALUE=DATE:20251217
SUMMARY:VYBRIQUE: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA210858\nDetails: https://t
 rialredline.com/drugs/vybrique-55273425
URL:https://trialredline.com/drugs/vybrique-55273425
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-310@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251216
DTEND;VALUE=DATE:20251217
SUMMARY:EXDENSUR: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761458\nDetails: https://t
 rialredline.com/drugs/exdensur-aebeb320
URL:https://trialredline.com/drugs/exdensur-aebeb320
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-308@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251217
DTEND;VALUE=DATE:20251218
SUMMARY:RYBREVANT FASPRO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761433\nDetails: https://t
 rialredline.com/drugs/rybrevant-faspro-eb9fc986
URL:https://trialredline.com/drugs/rybrevant-faspro-eb9fc986
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-307@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251218
DTEND;VALUE=DATE:20251219
SUMMARY:NUFYMCO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761473\nDetails: https://t
 rialredline.com/drugs/nufymco-ce352593
URL:https://trialredline.com/drugs/nufymco-ce352593
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-54@trialredline.com
DTSTAMP:20261006T075145Z
DTSTART;VALUE=DATE:20251219
DTEND;VALUE=DATE:20251220
SUMMARY:Aficamten: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219083\nDetails: https://t
 rialredline.com/drugs/aficamten-eb980b7c
URL:https://trialredline.com/drugs/aficamten-eb980b7c
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-304@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251219
DTEND;VALUE=DATE:20251220
SUMMARY:MYQORZO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219083\nDetails: https://t
 rialredline.com/drugs/myqorzo-0f92141f
URL:https://trialredline.com/drugs/myqorzo-0f92141f
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-305@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251219
DTEND;VALUE=DATE:20251220
SUMMARY:OZILTUS: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761457\nDetails: https://t
 rialredline.com/drugs/oziltus-25147e8d
URL:https://trialredline.com/drugs/oziltus-25147e8d
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-306@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251219
DTEND;VALUE=DATE:20251220
SUMMARY:BONCRESA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761456\nDetails: https://t
 rialredline.com/drugs/boncresa-440efd9c
URL:https://trialredline.com/drugs/boncresa-440efd9c
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-303@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251222
DTEND;VALUE=DATE:20251223
SUMMARY:MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA217338\nDetails: https://t
 rialredline.com/drugs/mucinex-12hr-cold-fever-multi-symptom-af35ad94
URL:https://trialredline.com/drugs/mucinex-12hr-cold-fever-multi-symptom-af
 35ad94
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-302@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251223
DTEND;VALUE=DATE:20251224
SUMMARY:YARTEMLEA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761152\nDetails: https://t
 rialredline.com/drugs/yartemlea-a9bb709b
URL:https://trialredline.com/drugs/yartemlea-a9bb709b
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-20@trialredline.com
DTSTAMP:20261006T075145Z
DTSTART;VALUE=DATE:20251230
DTEND;VALUE=DATE:20251231
SUMMARY:Tradipitant: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220152\nDetails: https://t
 rialredline.com/drugs/tradipitant-d8d545b2
URL:https://trialredline.com/drugs/tradipitant-d8d545b2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-301@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20251230
DTEND;VALUE=DATE:20251231
SUMMARY:NEREUS: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220152\nDetails: https://t
 rialredline.com/drugs/nereus-4ca3e668
URL:https://trialredline.com/drugs/nereus-4ca3e668
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-300@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260112
DTEND;VALUE=DATE:20260113
SUMMARY:ZYCUBO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA211241\nDetails: https://t
 rialredline.com/drugs/zycubo-cc03fa77
URL:https://trialredline.com/drugs/zycubo-cc03fa77
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-299@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260115
DTEND;VALUE=DATE:20260116
SUMMARY:FILKRI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761027\nDetails: https://t
 rialredline.com/drugs/filkri-2f814d3b
URL:https://trialredline.com/drugs/filkri-2f814d3b
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-298@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260126
DTEND;VALUE=DATE:20260127
SUMMARY:QUIOFIC: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA216395\nDetails: https://t
 rialredline.com/drugs/quiofic-99f484ee
URL:https://trialredline.com/drugs/quiofic-99f484ee
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-297@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260128
DTEND;VALUE=DATE:20260129
SUMMARY:YUVEZZI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220142\nDetails: https://t
 rialredline.com/drugs/yuvezzi-bbe027f0
URL:https://trialredline.com/drugs/yuvezzi-bbe027f0
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-296@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260203
DTEND;VALUE=DATE:20260204
SUMMARY:VYKOURA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220406\nDetails: https://t
 rialredline.com/drugs/vykoura-1867522c
URL:https://trialredline.com/drugs/vykoura-1867522c
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-295@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260212
DTEND;VALUE=DATE:20260213
SUMMARY:ADQUEY: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219474\nDetails: https://t
 rialredline.com/drugs/adquey-c69e0168
URL:https://trialredline.com/drugs/adquey-c69e0168
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-12@trialredline.com
DTSTAMP:20260926T055421Z
DTSTART;VALUE=DATE:20260213
DTEND;VALUE=DATE:20260214
SUMMARY:DISC-1459: Complete response letter
DESCRIPTION:FDA complete response letter\nCompany: Disc Medicine\, Inc (IRO
 N)\nSource: https://api.fda.gov/transparency/crl.json?search=file_name:CRL
 _NDA220707_20260213.pdf\nDetails: https://trialredline.com/drugs/disc-1459
 -f00aa3cb
URL:https://trialredline.com/drugs/disc-1459-f00aa3cb
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-294@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260213
DTEND;VALUE=DATE:20260214
SUMMARY:AVOPEF: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220200\nDetails: https://t
 rialredline.com/drugs/avopef-db9c5eb8
URL:https://trialredline.com/drugs/avopef-db9c5eb8
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-188@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260220
DTEND;VALUE=DATE:20260221
SUMMARY:Milsaperidone: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220358\nDetails: https://t
 rialredline.com/drugs/milsaperidone-c60da7b7
URL:https://trialredline.com/drugs/milsaperidone-c60da7b7
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-292@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260220
DTEND;VALUE=DATE:20260221
SUMMARY:BYSANTI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220358\nDetails: https://t
 rialredline.com/drugs/bysanti-8bddfff4
URL:https://trialredline.com/drugs/bysanti-8bddfff4
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-293@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260220
DTEND;VALUE=DATE:20260221
SUMMARY:FAVLYXA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220201\nDetails: https://t
 rialredline.com/drugs/favlyxa-979ed96c
URL:https://trialredline.com/drugs/favlyxa-979ed96c
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-291@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260223
DTEND;VALUE=DATE:20260224
SUMMARY:LOARGYS: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761211\nDetails: https://t
 rialredline.com/drugs/loargys-69b9c1ca
URL:https://trialredline.com/drugs/loargys-69b9c1ca
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-290@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260225
DTEND;VALUE=DATE:20260226
SUMMARY:DESMODA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219873\nDetails: https://t
 rialredline.com/drugs/desmoda-16516dc8
URL:https://trialredline.com/drugs/desmoda-16516dc8
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-288@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260227
DTEND;VALUE=DATE:20260228
SUMMARY:PREZCOBIX PED: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220092\nDetails: https://t
 rialredline.com/drugs/prezcobix-ped-d97560e7
URL:https://trialredline.com/drugs/prezcobix-ped-d97560e7
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-289@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260227
DTEND;VALUE=DATE:20260228
SUMMARY:YUVIWEL: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219164\nDetails: https://t
 rialredline.com/drugs/yuviwel-27ca6e62
URL:https://trialredline.com/drugs/yuviwel-27ca6e62
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-287@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260306
DTEND;VALUE=DATE:20260307
SUMMARY:PYLARIFY TRUVU: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220089\nDetails: https://t
 rialredline.com/drugs/pylarify-truvu-f3239d11
URL:https://trialredline.com/drugs/pylarify-truvu-f3239d11
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-5@trialredline.com
DTSTAMP:20260926T055419Z
DTSTART;VALUE=DATE:20260316
DTEND;VALUE=DATE:20260317
SUMMARY:ADX-102 Ophthalmic Solution (0.5%): Complete response letter
DESCRIPTION:FDA complete response letter\nCompany: Aldeyra Therapeutics\, I
 nc. (ALDX)\nSource: https://api.fda.gov/transparency/crl.json?search=file_
 name:CRL_NDA216442_20260316.pdf\nDetails: https://trialredline.com/drugs/a
 dx-102-ophthalmic-solution-0-5-45356f78
URL:https://trialredline.com/drugs/adx-102-ophthalmic-solution-0-5-45356f78
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-285@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260317
DTEND;VALUE=DATE:20260318
SUMMARY:LYNAVOY: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220295\nDetails: https://t
 rialredline.com/drugs/lynavoy-82a37383
URL:https://trialredline.com/drugs/lynavoy-82a37383
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-286@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260317
DTEND;VALUE=DATE:20260318
SUMMARY:ICOTYDE: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220149\nDetails: https://t
 rialredline.com/drugs/icotyde-c0505ef6
URL:https://trialredline.com/drugs/icotyde-c0505ef6
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-284@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260319
DTEND;VALUE=DATE:20260320
SUMMARY:FLAVALTA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA216564\nDetails: https://t
 rialredline.com/drugs/flavalta-01af9cfe
URL:https://trialredline.com/drugs/flavalta-01af9cfe
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-283@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260320
DTEND;VALUE=DATE:20260321
SUMMARY:ATONCY: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220320\nDetails: https://t
 rialredline.com/drugs/atoncy-cd687d02
URL:https://trialredline.com/drugs/atoncy-cd687d02
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-282@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260324
DTEND;VALUE=DATE:20260325
SUMMARY:AVLAYAH: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761485\nDetails: https://t
 rialredline.com/drugs/avlayah-63e536a1
URL:https://trialredline.com/drugs/avlayah-63e536a1
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-91@trialredline.com
DTSTAMP:20261006T075145Z
DTSTART;VALUE=DATE:20260325
DTEND;VALUE=DATE:20260326
SUMMARY:Relacorilant: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220641\nDetails: https://t
 rialredline.com/drugs/relacorilant-91d20dea
URL:https://trialredline.com/drugs/relacorilant-91d20dea
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-157@trialredline.com
DTSTAMP:20261006T075145Z
DTSTART;VALUE=DATE:20260325
DTEND;VALUE=DATE:20260326
SUMMARY:relacorilant: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220641\nDetails: https://t
 rialredline.com/drugs/relacorilant-acf86ae6
URL:https://trialredline.com/drugs/relacorilant-acf86ae6
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-281@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260325
DTEND;VALUE=DATE:20260326
SUMMARY:LIFYORLI (COPACKAGED): FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220641\nDetails: https://t
 rialredline.com/drugs/lifyorli-copackaged-0e9d95ca
URL:https://trialredline.com/drugs/lifyorli-copackaged-0e9d95ca
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-280@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260326
DTEND;VALUE=DATE:20260327
SUMMARY:AWIQLI FLEXTOUCH: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761326\nDetails: https://t
 rialredline.com/drugs/awiqli-flextouch-fc9c3e88
URL:https://trialredline.com/drugs/awiqli-flextouch-fc9c3e88
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-279@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260327
DTEND;VALUE=DATE:20260328
SUMMARY:PONLIMSI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761385\nDetails: https://t
 rialredline.com/drugs/ponlimsi-c0b8bb09
URL:https://trialredline.com/drugs/ponlimsi-c0b8bb09
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-278@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260401
DTEND;VALUE=DATE:20260402
SUMMARY:FOUNDAYO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220934\nDetails: https://t
 rialredline.com/drugs/foundayo-08f51204
URL:https://trialredline.com/drugs/foundayo-08f51204
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-277@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260420
DTEND;VALUE=DATE:20260421
SUMMARY:IDVYNSO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA216964\nDetails: https://t
 rialredline.com/drugs/idvynso-f67b3c42
URL:https://trialredline.com/drugs/idvynso-f67b3c42
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-276@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260429
DTEND;VALUE=DATE:20260430
SUMMARY:LANGLARA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761412\nDetails: https://t
 rialredline.com/drugs/langlara-d97e9125
URL:https://trialredline.com/drugs/langlara-d97e9125
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-273@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260501
DTEND;VALUE=DATE:20260502
SUMMARY:EVDI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220837\nDetails: https://t
 rialredline.com/drugs/evdi-4879130f
URL:https://trialredline.com/drugs/evdi-4879130f
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-274@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260501
DTEND;VALUE=DATE:20260502
SUMMARY:VEPPANU: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219835\nDetails: https://t
 rialredline.com/drugs/veppanu-9bd586bb
URL:https://trialredline.com/drugs/veppanu-9bd586bb
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-275@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260501
DTEND;VALUE=DATE:20260502
SUMMARY:JAKAFI XR: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA217180\nDetails: https://t
 rialredline.com/drugs/jakafi-xr-2deb1609
URL:https://trialredline.com/drugs/jakafi-xr-2deb1609
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-272@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260507
DTEND;VALUE=DATE:20260508
SUMMARY:ENNUMO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761147\nDetails: https://t
 rialredline.com/drugs/ennumo-577a0765
URL:https://trialredline.com/drugs/ennumo-577a0765
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-271@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260513
DTEND;VALUE=DATE:20260514
SUMMARY:BEQALZI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220711\nDetails: https://t
 rialredline.com/drugs/beqalzi-642fef0e
URL:https://trialredline.com/drugs/beqalzi-642fef0e
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-270@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260514
DTEND;VALUE=DATE:20260515
SUMMARY:TRIMBOW: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219622\nDetails: https://t
 rialredline.com/drugs/trimbow-e63274c3
URL:https://trialredline.com/drugs/trimbow-e63274c3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-267@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260515
DTEND;VALUE=DATE:20260516
SUMMARY:BAXFENDY: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219878\nDetails: https://t
 rialredline.com/drugs/baxfendy-fddd804e
URL:https://trialredline.com/drugs/baxfendy-fddd804e
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-268@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260515
DTEND;VALUE=DATE:20260516
SUMMARY:IMMGOLIS: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761452\nDetails: https://t
 rialredline.com/drugs/immgolis-09b17f5f
URL:https://trialredline.com/drugs/immgolis-09b17f5f
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-269@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260515
DTEND;VALUE=DATE:20260516
SUMMARY:IMMGOLIS INTRI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761452\nDetails: https://t
 rialredline.com/drugs/immgolis-intri-b2370c52
URL:https://trialredline.com/drugs/immgolis-intri-b2370c52
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-77@trialredline.com
DTSTAMP:20261006T075145Z
DTSTART;VALUE=DATE:20260522
DTEND;VALUE=DATE:20260523
SUMMARY:Bulevirtide: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761468\nDetails: https://t
 rialredline.com/drugs/bulevirtide-65e6fde8
URL:https://trialredline.com/drugs/bulevirtide-65e6fde8
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-265@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260522
DTEND;VALUE=DATE:20260523
SUMMARY:DIFFERIN EPIDUO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220736\nDetails: https://t
 rialredline.com/drugs/differin-epiduo-ed1d0c5b
URL:https://trialredline.com/drugs/differin-epiduo-ed1d0c5b
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-266@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260522
DTEND;VALUE=DATE:20260523
SUMMARY:HEPCLUDEX: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761468\nDetails: https://t
 rialredline.com/drugs/hepcludex-5cc262b5
URL:https://trialredline.com/drugs/hepcludex-5cc262b5
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-264@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260527
DTEND;VALUE=DATE:20260528
SUMMARY:DECNUPAZ: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761460\nDetails: https://t
 rialredline.com/drugs/decnupaz-32e88b71
URL:https://trialredline.com/drugs/decnupaz-32e88b71
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-260@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260529
DTEND;VALUE=DATE:20260530
SUMMARY:ZAYNICH: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220787\nDetails: https://t
 rialredline.com/drugs/zaynich-d7406b30
URL:https://trialredline.com/drugs/zaynich-d7406b30
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-261@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260529
DTEND;VALUE=DATE:20260530
SUMMARY:CYPSEDO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220482\nDetails: https://t
 rialredline.com/drugs/cypsedo-7cf06b5d
URL:https://trialredline.com/drugs/cypsedo-7cf06b5d
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-262@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260529
DTEND;VALUE=DATE:20260530
SUMMARY:XOCOVA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220442\nDetails: https://t
 rialredline.com/drugs/xocova-6bba6bd2
URL:https://trialredline.com/drugs/xocova-6bba6bd2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-263@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260529
DTEND;VALUE=DATE:20260530
SUMMARY:CAVHANZA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA217379\nDetails: https://t
 rialredline.com/drugs/cavhanza-d31ce267
URL:https://trialredline.com/drugs/cavhanza-d31ce267
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-258@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260603
SUMMARY:TIOCYSTIN: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA212927\nDetails: https://t
 rialredline.com/drugs/tiocystin-a6ad013b
URL:https://trialredline.com/drugs/tiocystin-a6ad013b
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-259@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260603
SUMMARY:RANLUSPEC: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761480\nDetails: https://t
 rialredline.com/drugs/ranluspec-fb4a2746
URL:https://trialredline.com/drugs/ranluspec-fb4a2746
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-257@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:AMBELVIST: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219627\nDetails: https://t
 rialredline.com/drugs/ambelvist-ba991e46
URL:https://trialredline.com/drugs/ambelvist-ba991e46
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-256@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260617
DTEND;VALUE=DATE:20260618
SUMMARY:UTEBZI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA215960\nDetails: https://t
 rialredline.com/drugs/utebzi-7eddd3f3
URL:https://trialredline.com/drugs/utebzi-7eddd3f3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-255@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:NAVITRUX: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220436\nDetails: https://t
 rialredline.com/drugs/navitrux-3df4fa3d
URL:https://trialredline.com/drugs/navitrux-3df4fa3d
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-254@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260626
DTEND;VALUE=DATE:20260627
SUMMARY:LUMVOA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761530\nDetails: https://t
 rialredline.com/drugs/lumvoa-b0262f88
URL:https://trialredline.com/drugs/lumvoa-b0262f88
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-10@trialredline.com
DTSTAMP:20260926T055421Z
DTSTART;VALUE=DATE:20260629
DTEND;VALUE=DATE:20260630
SUMMARY:Oxylanthanum Carbonate: Complete response letter
DESCRIPTION:FDA complete response letter\nCompany: Unicycive Therapeutics\,
  Inc (UNCY)\nSource: https://api.fda.gov/transparency/crl.json?search=file
 _name:CRL_NDA218607_20260629.pdf\nDetails: https://trialredline.com/drugs/
 oxylanthanum-carbonate-dd31e075
URL:https://trialredline.com/drugs/oxylanthanum-carbonate-dd31e075
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-253@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260707
DTEND;VALUE=DATE:20260708
SUMMARY:TRUTAKNA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761486\nDetails: https://t
 rialredline.com/drugs/trutakna-95a3ea77
URL:https://trialredline.com/drugs/trutakna-95a3ea77
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-252@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260709
DTEND;VALUE=DATE:20260710
SUMMARY:SARCLISA ESCENA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761445\nDetails: https://t
 rialredline.com/drugs/sarclisa-escena-ade47fa5
URL:https://trialredline.com/drugs/sarclisa-escena-ade47fa5
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-251@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260710
DTEND;VALUE=DATE:20260711
SUMMARY:ZYOGREEN: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA218579\nDetails: https://t
 rialredline.com/drugs/zyogreen-3b0ac2f7
URL:https://trialredline.com/drugs/zyogreen-3b0ac2f7
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-162@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260715
SUMMARY:Gedatolisib: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219908\nDetails: https://t
 rialredline.com/drugs/gedatolisib-0e18c69a
URL:https://trialredline.com/drugs/gedatolisib-0e18c69a
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-250@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260714
DTEND;VALUE=DATE:20260715
SUMMARY:REVTORPYK: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219908\nDetails: https://t
 rialredline.com/drugs/revtorpyk-72da59e2
URL:https://trialredline.com/drugs/revtorpyk-72da59e2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-249@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260715
DTEND;VALUE=DATE:20260716
SUMMARY:LIPFENDRA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220848\nDetails: https://t
 rialredline.com/drugs/lipfendra-b94bec05
URL:https://trialredline.com/drugs/lipfendra-b94bec05
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-248@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260722
DTEND;VALUE=DATE:20260723
SUMMARY:JIDEYTRO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220185\nDetails: https://t
 rialredline.com/drugs/jideytro-b8c11dd8
URL:https://trialredline.com/drugs/jideytro-b8c11dd8
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-245@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260724
DTEND;VALUE=DATE:20260725
SUMMARY:SIMTRIYO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA218145\nDetails: https://t
 rialredline.com/drugs/simtriyo-63cb78eb
URL:https://trialredline.com/drugs/simtriyo-63cb78eb
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-246@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260724
DTEND;VALUE=DATE:20260725
SUMMARY:GARZULYS: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761497\nDetails: https://t
 rialredline.com/drugs/garzulys-4fc6dcba
URL:https://trialredline.com/drugs/garzulys-4fc6dcba
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-247@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260724
DTEND;VALUE=DATE:20260725
SUMMARY:LYTENAVA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761320\nDetails: https://t
 rialredline.com/drugs/lytenava-1cead6d8
URL:https://trialredline.com/drugs/lytenava-1cead6d8
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-244@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260728
DTEND;VALUE=DATE:20260729
SUMMARY:GWYN LO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219990\nDetails: https://t
 rialredline.com/drugs/gwyn-lo-d8ffd1c6
URL:https://trialredline.com/drugs/gwyn-lo-d8ffd1c6
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-242@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260729
DTEND;VALUE=DATE:20260730
SUMMARY:QLONILIK: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA221094\nDetails: https://t
 rialredline.com/drugs/qlonilik-f57cf42b
URL:https://trialredline.com/drugs/qlonilik-f57cf42b
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-243@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260729
DTEND;VALUE=DATE:20260730
SUMMARY:GLYCOPHOS: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220381\nDetails: https://t
 rialredline.com/drugs/glycophos-5c59d60a
URL:https://trialredline.com/drugs/glycophos-5c59d60a
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-241@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260731
DTEND;VALUE=DATE:20260801
SUMMARY:ZIMRIXBY: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761376\nDetails: https://t
 rialredline.com/drugs/zimrixby-4736fdad
URL:https://trialredline.com/drugs/zimrixby-4736fdad
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-240@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260805
DTEND;VALUE=DATE:20260806
SUMMARY:ORZEYFUL: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220860\nDetails: https://t
 rialredline.com/drugs/orzeyful-768cfc86
URL:https://trialredline.com/drugs/orzeyful-768cfc86
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-238@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260813
DTEND;VALUE=DATE:20260814
SUMMARY:ZENBEXUS: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA221075\nDetails: https://t
 rialredline.com/drugs/zenbexus-0966c3ea
URL:https://trialredline.com/drugs/zenbexus-0966c3ea
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-239@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260813
DTEND;VALUE=DATE:20260814
SUMMARY:TAUKLARIFY: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220496\nDetails: https://t
 rialredline.com/drugs/tauklarify-510c5788
URL:https://trialredline.com/drugs/tauklarify-510c5788
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-237@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260819
DTEND;VALUE=DATE:20260820
SUMMARY:PASATRU: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761508\nDetails: https://t
 rialredline.com/drugs/pasatru-486f68cb
URL:https://trialredline.com/drugs/pasatru-486f68cb
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-143@trialredline.com
DTSTAMP:20261006T075145Z
DTSTART;VALUE=DATE:20260826
DTEND;VALUE=DATE:20260827
SUMMARY:daraxonrasib: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220910\nDetails: https://t
 rialredline.com/drugs/daraxonrasib-e0b17ee5
URL:https://trialredline.com/drugs/daraxonrasib-e0b17ee5
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-235@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260826
DTEND;VALUE=DATE:20260827
SUMMARY:RASONQUE: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220910\nDetails: https://t
 rialredline.com/drugs/rasonque-a0af1cb4
URL:https://trialredline.com/drugs/rasonque-a0af1cb4
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-236@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260826
DTEND;VALUE=DATE:20260827
SUMMARY:VOBRIG: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA213225\nDetails: https://t
 rialredline.com/drugs/vobrig-e17fe131
URL:https://trialredline.com/drugs/vobrig-e17fe131
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1482@trialredline.com
DTSTAMP:20261116T204043Z
DTSTART;VALUE=DATE:20260826
DTEND;VALUE=DATE:20260827
SUMMARY:Daraxonrasib: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220910\nDetails: https://t
 rialredline.com/drugs/daraxonrasib-9ab42892
URL:https://trialredline.com/drugs/daraxonrasib-9ab42892
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-232@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:BIXLENVO SUNLENCA STARTER PACK (COPACKAGED): FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA221443\nDetails: https://t
 rialredline.com/drugs/bixlenvo-sunlenca-starter-pack-copackaged-7a8be62a
URL:https://trialredline.com/drugs/bixlenvo-sunlenca-starter-pack-copackage
 d-7a8be62a
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-233@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:BIXLENVO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA221104\nDetails: https://t
 rialredline.com/drugs/bixlenvo-bbd3118b
URL:https://trialredline.com/drugs/bixlenvo-bbd3118b
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-234@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:LISRAYA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220106\nDetails: https://t
 rialredline.com/drugs/lisraya-5662afe1
URL:https://trialredline.com/drugs/lisraya-5662afe1
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-231@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260828
DTEND;VALUE=DATE:20260829
SUMMARY:MIMRYLO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220605\nDetails: https://t
 rialredline.com/drugs/mimrylo-e04db274
URL:https://trialredline.com/drugs/mimrylo-e04db274
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-229@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260903
DTEND;VALUE=DATE:20260904
SUMMARY:OMCAZIO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220613\nDetails: https://t
 rialredline.com/drugs/omcazio-262744a9
URL:https://trialredline.com/drugs/omcazio-262744a9
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-230@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260903
DTEND;VALUE=DATE:20260904
SUMMARY:ZANVASTRO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220210\nDetails: https://t
 rialredline.com/drugs/zanvastro-016723ef
URL:https://trialredline.com/drugs/zanvastro-016723ef
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-228@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260904
DTEND;VALUE=DATE:20260905
SUMMARY:ETCAMAH: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220359\nDetails: https://t
 rialredline.com/drugs/etcamah-0d23c7b5
URL:https://trialredline.com/drugs/etcamah-0d23c7b5
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-226@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260911
DTEND;VALUE=DATE:20260912
SUMMARY:PIXCLARA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA218592\nDetails: https://t
 rialredline.com/drugs/pixclara-1c9f64f3
URL:https://trialredline.com/drugs/pixclara-1c9f64f3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-227@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260911
DTEND;VALUE=DATE:20260912
SUMMARY:ISEMBYLD: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761463\nDetails: https://t
 rialredline.com/drugs/isembyld-46781659
URL:https://trialredline.com/drugs/isembyld-46781659
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-225@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260914
DTEND;VALUE=DATE:20260915
SUMMARY:BEXLUTRY: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA218525\nDetails: https://t
 rialredline.com/drugs/bexlutry-459a0b98
URL:https://trialredline.com/drugs/bexlutry-459a0b98
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1465@trialredline.com
DTSTAMP:20261103T211003Z
DTSTART;VALUE=DATE:20260917
DTEND;VALUE=DATE:20260918
SUMMARY:UX111: FDA approval decision
DESCRIPTION:FDA CBER biologic approval\nCondition: Indicated for the treatm
 ent of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS I
 IIA\, Sanfilippo Syndrome type A) in pediatric patients with preserved neu
 rodevelopmental function.\nCompany: Ultragenyx Pharmaceutical Inc (RARE)\n
 Source: https://www.fda.gov/vaccines-blood-biologics/development-approval-
 process-cber/2026-biological-license-application-approvals#125845%2F0\nDet
 ails: https://trialredline.com/drugs/ux111-cac83570
URL:https://trialredline.com/drugs/ux111-cac83570
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-223@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260923
DTEND;VALUE=DATE:20260924
SUMMARY:LYRFIGTU: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220425\nDetails: https://t
 rialredline.com/drugs/lyrfigtu-4bfa218e
URL:https://trialredline.com/drugs/lyrfigtu-4bfa218e
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-224@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260923
DTEND;VALUE=DATE:20260924
SUMMARY:ONSWIK: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761408\nDetails: https://t
 rialredline.com/drugs/onswik-400f4c44
URL:https://trialredline.com/drugs/onswik-400f4c44
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-219@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:ATEBRIOZ: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA221198\nDetails: https://t
 rialredline.com/drugs/atebrioz-b0484436
URL:https://trialredline.com/drugs/atebrioz-b0484436
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-220@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:JUVMO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220415\nDetails: https://t
 rialredline.com/drugs/juvmo-e261d32a
URL:https://trialredline.com/drugs/juvmo-e261d32a
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-221@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:ZUEINO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA218379\nDetails: https://t
 rialredline.com/drugs/zueino-c10b91e5
URL:https://trialredline.com/drugs/zueino-c10b91e5
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-222@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:DEGEVMA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761481\nDetails: https://t
 rialredline.com/drugs/degevma-a54062c3
URL:https://trialredline.com/drugs/degevma-a54062c3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1453@trialredline.com
DTSTAMP:20261019T204031Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:LAMLIQUE: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA221109\nDetails: https://t
 rialredline.com/drugs/lamlique-16fe3a5c
URL:https://trialredline.com/drugs/lamlique-16fe3a5c
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1454@trialredline.com
DTSTAMP:20261019T204031Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:JUVMO (COPACKAGED): FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220415\nDetails: https://t
 rialredline.com/drugs/juvmo-copackaged-6ccd9377
URL:https://trialredline.com/drugs/juvmo-copackaged-6ccd9377
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-218@trialredline.com
DTSTAMP:20261006T075146Z
DTSTART;VALUE=DATE:20260928
DTEND;VALUE=DATE:20260929
SUMMARY:EMCITATE: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220963\nDetails: https://t
 rialredline.com/drugs/emcitate-4e99c581
URL:https://trialredline.com/drugs/emcitate-4e99c581
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1452@trialredline.com
DTSTAMP:20261019T204031Z
DTSTART;VALUE=DATE:20261008
DTEND;VALUE=DATE:20261009
SUMMARY:WELTRUZA: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219007\nDetails: https://t
 rialredline.com/drugs/weltruza-acfca8bf
URL:https://trialredline.com/drugs/weltruza-acfca8bf
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1450@trialredline.com
DTSTAMP:20261019T204031Z
DTSTART;VALUE=DATE:20261009
DTEND;VALUE=DATE:20261010
SUMMARY:HOVILPR: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA221154\nDetails: https://t
 rialredline.com/drugs/hovilpr-359b597e
URL:https://trialredline.com/drugs/hovilpr-359b597e
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1451@trialredline.com
DTSTAMP:20261019T204031Z
DTSTART;VALUE=DATE:20261009
DTEND;VALUE=DATE:20261010
SUMMARY:ISOVUE READI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220583\nDetails: https://t
 rialredline.com/drugs/isovue-readi-6d82789f
URL:https://trialredline.com/drugs/isovue-readi-6d82789f
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1464@trialredline.com
DTSTAMP:20261102T204034Z
DTSTART;VALUE=DATE:20261009
DTEND;VALUE=DATE:20261010
SUMMARY:HOVILPRI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA221154\nDetails: https://t
 rialredline.com/drugs/hovilpri-73404cf3
URL:https://trialredline.com/drugs/hovilpri-73404cf3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1461@trialredline.com
DTSTAMP:20261026T204037Z
DTSTART;VALUE=DATE:20261016
DTEND;VALUE=DATE:20261017
SUMMARY:YULZETY: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA221033\nDetails: https://t
 rialredline.com/drugs/yulzety-8bccccc1
URL:https://trialredline.com/drugs/yulzety-8bccccc1
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1463@trialredline.com
DTSTAMP:20261102T204034Z
DTSTART;VALUE=DATE:20261016
DTEND;VALUE=DATE:20261017
SUMMARY:BRYTLY: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220341\nDetails: https://t
 rialredline.com/drugs/brytly-d9146a88
URL:https://trialredline.com/drugs/brytly-d9146a88
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1459@trialredline.com
DTSTAMP:20261026T204037Z
DTSTART;VALUE=DATE:20261019
DTEND;VALUE=DATE:20261020
SUMMARY:CALREZDY: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219456\nDetails: https://t
 rialredline.com/drugs/calrezdy-7a0e1170
URL:https://trialredline.com/drugs/calrezdy-7a0e1170
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1460@trialredline.com
DTSTAMP:20261026T204037Z
DTSTART;VALUE=DATE:20261019
DTEND;VALUE=DATE:20261020
SUMMARY:CIENBY: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA219455\nDetails: https://t
 rialredline.com/drugs/cienby-5c274d70
URL:https://trialredline.com/drugs/cienby-5c274d70
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1458@trialredline.com
DTSTAMP:20261026T204037Z
DTSTART;VALUE=DATE:20261020
DTEND;VALUE=DATE:20261021
SUMMARY:HIBSAGO: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA221276\nDetails: https://t
 rialredline.com/drugs/hibsago-cfb98fca
URL:https://trialredline.com/drugs/hibsago-cfb98fca
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1485@trialredline.com
DTSTAMP:20261116T204043Z
DTSTART;VALUE=DATE:20261027
DTEND;VALUE=DATE:20261028
SUMMARY:LUCAMZI: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:BLA761187\nDetails: https://t
 rialredline.com/drugs/lucamzi-856f348d
URL:https://trialredline.com/drugs/lucamzi-856f348d
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1484@trialredline.com
DTSTAMP:20261116T204043Z
DTSTART;VALUE=DATE:20261029
DTEND;VALUE=DATE:20261030
SUMMARY:AXYCIS: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA220748\nDetails: https://t
 rialredline.com/drugs/axycis-8d6a8c61
URL:https://trialredline.com/drugs/axycis-8d6a8c61
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1483@trialredline.com
DTSTAMP:20261116T204043Z
DTSTART;VALUE=DATE:20261109
DTEND;VALUE=DATE:20261110
SUMMARY:OXDERYS: FDA approval decision
DESCRIPTION:FDA original application approval\nSource: https://api.fda.gov/
 drug/drugsfda.json?search=application_number:NDA221093\nDetails: https://t
 rialredline.com/drugs/oxderys-fde520cf
URL:https://trialredline.com/drugs/oxderys-fde520cf
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1475@trialredline.com
DTSTAMP:20261107T171338Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:bezuclastinib: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: GIST\nCompany: Co
 gent Biosciences\, Inc. (COGT)\nSource: https://www.sec.gov/Archives/edgar
 /data/1622229/000119312526449926/0001193125-26-449926.txt\nDetails: https:
 //trialredline.com/drugs/bezuclastinib-ee1ff4b3
URL:https://trialredline.com/drugs/bezuclastinib-ee1ff4b3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1472@trialredline.com
DTSTAMP:20261107T171230Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Lorundrostat: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: hypertension in c
 ombination with other antihypertensive drugs\nCompany: Mineralys Therapeut
 ics Inc. (MLYS)\nSource: https://www.sec.gov/Archives/edgar/data/1933414/0
 00193341426000144/0001933414-26-000144.txt\nDetails: https://trialredline.
 com/drugs/lorundrostat-20fa9556
URL:https://trialredline.com/drugs/lorundrostat-20fa9556
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1473@trialredline.com
DTSTAMP:20261107T171232Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Lorundrostat: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: treatment of hype
 rtension in combination with other antihypertensive drugs\nCompany: Minera
 lys Therapeutics Inc. (MLYS)\nSource: https://www.sec.gov/Archives/edgar/d
 ata/1933414/000193341426000142/0001933414-26-000142.txt\nDetails: https://
 trialredline.com/drugs/lorundrostat-20fa9556
URL:https://trialredline.com/drugs/lorundrostat-20fa9556
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1474@trialredline.com
DTSTAMP:20261107T171332Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:bezuclastinib: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: NonAdvSM\nCompany
 : Cogent Biosciences\, Inc. (COGT)\nSource: https://www.sec.gov/Archives/e
 dgar/data/1622229/000119312526449963/0001193125-26-449963.txt\nDetails: ht
 tps://trialredline.com/drugs/bezuclastinib-ee1ff4b3
URL:https://trialredline.com/drugs/bezuclastinib-ee1ff4b3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1476@trialredline.com
DTSTAMP:20261108T171048Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:bezuclastinib: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: NonAdvSM\nCompany
 : Cogent Biosciences\, Inc. (COGT)\nSource: https://www.sec.gov/Archives/e
 dgar/data/1622229/000119312526449926/0001193125-26-449926.txt\nDetails: ht
 tps://trialredline.com/drugs/bezuclastinib-ee1ff4b3
URL:https://trialredline.com/drugs/bezuclastinib-ee1ff4b3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1469@trialredline.com
DTSTAMP:20261107T171103Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Mitapivat: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: sickle cell disea
 se\nCompany: Agios Pharmaceuticals\, Inc. (AGIO)\nSource: https://www.sec.
 gov/Archives/edgar/data/1439222/000143922226000131/0001439222-26-000131.tx
 t\nDetails: https://trialredline.com/drugs/mitapivat-1d8d8556
URL:https://trialredline.com/drugs/mitapivat-1d8d8556
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1470@trialredline.com
DTSTAMP:20261107T171109Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Mitapivat: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: SCD\nCompany: Agi
 os Pharmaceuticals\, Inc. (AGIO)\nSource: https://www.sec.gov/Archives/edg
 ar/data/1439222/000143922226000131/0001439222-26-000131.txt\nDetails: http
 s://trialredline.com/drugs/mitapivat-1d8d8556
URL:https://trialredline.com/drugs/mitapivat-1d8d8556
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1471@trialredline.com
DTSTAMP:20261107T171113Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Mitapivat: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: sickle cell disea
 se\nCompany: Agios Pharmaceuticals\, Inc. (AGIO)\nSource: https://www.sec.
 gov/Archives/edgar/data/1439222/000143922226000129/0001439222-26-000129.tx
 t\nDetails: https://trialredline.com/drugs/mitapivat-1d8d8556
URL:https://trialredline.com/drugs/mitapivat-1d8d8556
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-17@trialredline.com
DTSTAMP:20260926T055808Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Tinlarebant: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: Stargardt disease
  type 1\nCompany: Belite Bio\, Inc (BLTE)\nSource: https://www.sec.gov/Arc
 hives/edgar/data/1889109/000110465926105608/0001104659-26-105608.txt\nDeta
 ils: https://trialredline.com/drugs/tinlarebant-a805b78c
URL:https://trialredline.com/drugs/tinlarebant-a805b78c
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1481@trialredline.com
DTSTAMP:20261113T171115Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Tinlarebant: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: Stargardt disease
  type 1 (STGD1)\nCompany: Belite Bio\, Inc (BLTE)\nSource: https://www.sec
 .gov/Archives/edgar/data/1889109/000110465926125573/0001104659-26-125573.t
 xt\nDetails: https://trialredline.com/drugs/tinlarebant-a805b78c
URL:https://trialredline.com/drugs/tinlarebant-a805b78c
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1479@trialredline.com
DTSTAMP:20261111T171244Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:AL102: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCompany: Immunome\, Inc. (IM
 NM)\nSource: https://www.sec.gov/Archives/edgar/data/1472012/0001193125264
 53597/0001193125-26-453597.txt\nDetails: https://trialredline.com/drugs/al
 102-8f4b5fec
URL:https://trialredline.com/drugs/al102-8f4b5fec
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1480@trialredline.com
DTSTAMP:20261111T171249Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:AL102: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCompany: Immunome\, Inc. (IM
 NM)\nSource: https://www.sec.gov/Archives/edgar/data/1472012/0001193125264
 53556/0001193125-26-453556.txt\nDetails: https://trialredline.com/drugs/al
 102-8f4b5fec
URL:https://trialredline.com/drugs/al102-8f4b5fec
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1@trialredline.com
DTSTAMP:20260925T043857Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:AXS-12 (reboxetine): PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: cataplexy in narc
 olepsy\nCompany: Axsome Therapeutics\, Inc. (AXSM)\nSource: https://www.se
 c.gov/Archives/edgar/data/1579428/000119312526304039/axsm-ex99_1.htm\nDeta
 ils: https://trialredline.com/drugs/axs-12-reboxetine-1f15912f
URL:https://trialredline.com/drugs/axs-12-reboxetine-1f15912f
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1462@trialredline.com
DTSTAMP:20261102T171014Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:AXS-12 (reboxetine): PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: cataplexy in narc
 olepsy\nCompany: Axsome Therapeutics\, Inc. (AXSM)\nSource: https://www.se
 c.gov/Archives/edgar/data/1579428/000119312526442628/0001193125-26-442628.
 txt\nDetails: https://trialredline.com/drugs/axs-12-reboxetine-1f15912f
URL:https://trialredline.com/drugs/axs-12-reboxetine-1f15912f
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1466@trialredline.com
DTSTAMP:20261107T171013Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:UGN-103: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: recurrent low-gra
 de intermediate risk NMIBC\nCompany: UroGen Pharma Ltd. (URGN)\nSource: ht
 tps://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/000143774
 9-26-034780.txt\nDetails: https://trialredline.com/drugs/ugn-103-7135c598
URL:https://trialredline.com/drugs/ugn-103-7135c598
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1467@trialredline.com
DTSTAMP:20261107T171018Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:UGN-103: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: adults with recur
 rent low-grade intermediate risk NMIBC\nCompany: UroGen Pharma Ltd. (URGN)
 \nSource: https://www.sec.gov/Archives/edgar/data/1668243/0001437749260347
 80/0001437749-26-034780.txt\nDetails: https://trialredline.com/drugs/ugn-1
 03-7135c598
URL:https://trialredline.com/drugs/ugn-103-7135c598
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1468@trialredline.com
DTSTAMP:20261107T171025Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:UGN-103: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: recurrent LG-IR-N
 MIBC\nCompany: UroGen Pharma Ltd. (URGN)\nSource: https://www.sec.gov/Arch
 ives/edgar/data/1668243/000143774926034769/0001437749-26-034769.txt\nDetai
 ls: https://trialredline.com/drugs/ugn-103-7135c598
URL:https://trialredline.com/drugs/ugn-103-7135c598
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:regulatory-event-1477@trialredline.com
DTSTAMP:20261108T171049Z
DTSTART;VALUE=DATE:20270629
DTEND;VALUE=DATE:20270630
SUMMARY:bezuclastinib: PDUFA date
DESCRIPTION:Company-disclosed PDUFA goal date\nCondition: AdvSM\nCompany: C
 ogent Biosciences\, Inc. (COGT)\nSource: https://www.sec.gov/Archives/edga
 r/data/1622229/000119312526449926/0001193125-26-449926.txt\nDetails: https
 ://trialredline.com/drugs/bezuclastinib-ee1ff4b3
URL:https://trialredline.com/drugs/bezuclastinib-ee1ff4b3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
